Eton Pharmaceuticals (ETON) Gains from Sales and Divestitures (2019 - 2025)
Historic Gains from Sales and Divestitures for Eton Pharmaceuticals (ETON) over the last 6 years, with Q3 2025 value amounting to $84204.0.
- Eton Pharmaceuticals' Gains from Sales and Divestitures fell 685.6% to $84204.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $84204.0, marking a year-over-year decrease of 685.6%. This contributed to the annual value of $90402.0 for FY2024, which is 109.41% down from last year.
- Per Eton Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $84204.0 for Q3 2025, which was down 685.6% from $889.0 recorded in Q2 2025.
- Over the past 5 years, Eton Pharmaceuticals' Gains from Sales and Divestitures peaked at $91402.0 during Q3 2023, and registered a low of $889.0 during Q2 2025.
- In the last 4 years, Eton Pharmaceuticals' Gains from Sales and Divestitures had a median value of $90402.0 in 2024 and averaged $65185.1.
- In the last 5 years, Eton Pharmaceuticals' Gains from Sales and Divestitures changed by 0.0% in 2021 and then tumbled by 685.6% in 2025.
- Over the past 4 years, Eton Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $7595.0 in 2021, then surged by 1103.45% to $91402.0 in 2023, then decreased by 1.09% to $90402.0 in 2024, then fell by 6.86% to $84204.0 in 2025.
- Its Gains from Sales and Divestitures was $84204.0 in Q3 2025, compared to $889.0 in Q2 2025 and $90402.0 in Q4 2024.